Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in India / NCT07163260
Enrolling by invitation Observational

Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia

NCT07163260 · tracked via the Priya Life Science India tracker
Sponsor
Novo Nordisk A/S
Phase
Observational
Started
2025-01-31
Last updated
2025-10-24

Condition(s) studied

Haemophilia

Investigational drug(s) / intervention(s)

No treatment given

No treatment given: No treatment given

Study summary

This study will help to better understand the course of disease in people with haemophilia (A or B \[with or without inhibitors\]) and the haemophilia care scenario in the selected countries and the experience so far in dealing with the condition. This is a survey-based study; hence no medications or other treatments will be provided to participants as a part of this study.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: For Experienced/Senior Treating Physicians * Experienced/senior haematologist treating haemophilia (adult or paediatric) or physician treating patients with haemophilia. (PWH), with greater than 5 years of experience. * Able to communicate in English or country specific language. * Agree/sign informed consent before data collection. For Patients Organisations * Patient organisation supporting haemophilia. * Expert having greater than 3 years of work experience with the patient organisation. * Expert level understanding of haemophilia landscape and care pathway in the relevant country. * Able to communicate in English or country specific language. * Agree/sign informed consent before data collection. For Patients/Caregivers 1. Patients of all age groups, diagnosed with haemophilia A or haemophilia B (with or without inhibitors) for greater than 2 years. 2. For patients less than 18 years of age (\*less than 19 years for South Korea), their caregivers aged greater than or equal to 18 years (\*greater than or equal to19 years for South Korea) should sign the informed consent. \*For South Korea, the adult age is 19 years. 3. Able to communicate in English or country specific language. 4. Agree/sign informed consent before data collection. Exclusion Criteria: * There is no explicit exclusion criterion in this study, thus any participants group who answers "no" to any of the inclusion criteria will be excluded from the study.

Primary outcome measure(s)

  • Estimated prevalence of haemophilia — From start of data collection to end of data collection (approximately 5 months)
    Proportion \[%\] of individuals in a population
  • Estimated incidence of haemophilia — From start of data collection to end of data collection (approximately 5 months)
    Number of new cases of haemophilia
  • Estimated proportion of patients with haemophilia (PWH) who develop inhibitors (%) — From start of data collection to end of data collection (approximately 5 months)
    proportion \[%\] of individuals in a population

Trial sites (4)

FacilityCityRegionStatus
Novo Nordisk Investigational Site Bangalore Karnataka
Novo Nordisk Investigational Site Kuala Lumpur Malaysia
Novo Nordisk Investigational Site Seoul South Korea
Novo Nordisk Investigational Site Bangkok Thailand

More Novo Nordisk A/S trials in India

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Active, not recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy Recruiting
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors Active, not recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07163260 on ClinicalTrials.gov ↗ ← All trials in India